Lawsuit filed for Investors in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) in effort to recover Losses

An investor, who purchased shares of Medpace Holdings, Inc. (NASDAQ: MEDP), filed a lawsuit over alleged violations of Federal Securities Laws by Medpace Holdings, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Medpace Holdings, Inc. (NASDAQ: MEDP) have certain options and for certain investors are short and strict deadlines running. Deadline: June 8, 2026. NASDAQ: MEDP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cincinnati, OH based Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

On February 9, 2026, Medpace released fourth quarter 2025 earnings results revealing a book-to-bill ratio of 1.04, well below Medpace's guidance. Medpace Holdings, Inc. (NASDAQ: MEDP) reported that its annual Total Revenue rose from over $2.1 billion in 2024 to over $2.5 billion in 2025 and that its Net Income increased from $404.38 million in 2024 to $451.12 million in 2025.

Shares of Medpace Holdings, Inc. (NASDAQ: MEDP) declined from $628.92 per share on January 16, 2026, to $392.35 per share on February 12, 2026.

According to the complaint the plaintiff alleges on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ: MEDP) common shares between April 22, 2025 and February 9, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 22, 2025 and February 9, 2026, the defendants made false and/or misleading statements and/or failed to disclose that Medpace consistently oversold Medpace's projected book-to-bill ratio for fourth quarter 2025, that Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio, that Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment,that Medpace reassured investors that Medpace was not concerned about the lack of diversity in its pre-backlog, and that Medpace management stated that, despite the uptick in metabolic growth, Medpace's upside was broad-based and not isolated to any handful of studies.

Those who purchased shares of Medpace Holdings, Inc. (NASDAQ: MEDP) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.